This National Institutes of Health grant addresses critical issues surrounding health equity, drug costs, and access to new or repurposed treatments for Alzheimer’s Disease and related dementias (AD/ADRD). This grant specifically targets racial and ethnic minority populations, aiming to identify their preferences for pharmacological treatments and assess existing cost barriers. It also seeks to quantify expenditures and health-related quality of life among those interested in novel AD/ADRD therapies. The initial R61 phase supports rigorous stakeholder engagement to understand demand for new drugs. Successful projects transition to an R33 phase, focusing on implementing robust modeling of costs and health-related quality of life, followed by disseminating these vital findings. This initiative seeks to ensure equitable access to AD/ADRD treatments.
Opportunity ID: 349400
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-AG-24-050 |
| Funding Opportunity Title: | Health Equity and the Cost of Novel Treatments for Alzheimers Disease (AD) and AD-Related Dementias (ADRD) (R61/R33 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.866 — Aging Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jul 19, 2023 |
| Last Updated Date: | Jul 19, 2023 |
| Original Closing Date for Applications: | Oct 31, 2023 |
| Current Closing Date for Applications: | Oct 31, 2023 |
| Archive Date: | Dec 06, 2023 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $200,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Native American tribal governments (Federally recognized) For profit organizations other than small businesses Small businesses Others (see text field entitled “Additional Information on Eligibility” for clarification) Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education State governments Special district governments City or township governments County governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities Private institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Independent school districts |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This NOFO invites R61/R33 applications that address health equity, drug costs, and access to new therapeutics or repurposed drugs for Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD). Successful applications will seek to identify preferences for pharmacological treatment among racial and ethnic minority people living with AD/ADRD, assess whether cost barriers to pharmacological care exist for racial and ethnic minority people living with AD/ADRD, and quantify expenditures and health- related quality of life (HRQoL) among people interested in receiving novel or repurposed drugs for AD/ADRD. This NOFO will support a study development phase (R61) to conduct rigorous stakeholder engagement with racial and ethnic minority groups to identify, measure, and assess the demand for new and repurposed drugs, and if successful, grantees will transition to an R33 phase for implementation of rigorous modeling of costs and health-related quality of life and dissemination of model findings. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-24-050.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 349400 Full Announcement-RFA-AG-24-050 -> RFA-AG-24-050-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00282602 | Sep 29, 2023 | Oct 31, 2023 | View |
Package 1
Mandatory forms
349400 RR_SF424_5_0-5.0.pdf
349400 PHS398_CoverPageSupplement_5_0-5.0.pdf
349400 RR_OtherProjectInfo_1_4-1.4.pdf
349400 PerformanceSite_4_0-4.0.pdf
349400 RR_KeyPersonExpanded_4_0-4.0.pdf
349400 RR_Budget10_3_0-3.0.pdf
349400 PHS398_ResearchPlan_5_0-5.0.pdf
349400 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
349400 RR_SubawardBudget10_30_3_0-3.0.pdf
349400 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
